Navigation Links
GSK and Pfizer Innovative Agreement Creates Specialist HIV Company
Date:4/16/2009

LONDON, April 16 /PRNewswire-FirstCall/ -- Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company.

The deal will see the drug giants combine their existing HIV product and their pipelines with GSK holding 85% of the company and Pfizer 15%.

The deal will be marginally dilutive to GSK earnings in the first two years but in a video interview Group CEO Andrew Witty said there were longer term benefits for GSK shareholders.

"Today we own 100 per cent of a pipeline with three assets in it. Tomorrow we'll own 85 per cent of a pipeline with somewhere between five and seven assets in it."

The GSK boss said he was also committed to maximising the cost savings from the combination.

The interview and transcript are available now on http://w3.cantos.com/glaxosmithkline.

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
2. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
3. JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market
4. Hovione Buys Pfizers Loughbeg API Facility
5. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
6. Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods
7. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
8. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
9. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
10. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
11. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... According to a report by Transparency Market ... due to the presence of a large pool of participants; however, ... , and Sigma-Aldrich, compete with each other in this market. With ... than 76% of this market in 2016.  ... As of now, a large number of ...
(Date:3/22/2017)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major ... and GSK to generate genetic sequence data from the 500,000 ... enable researchers to gain valuable insights to support advances in ... serious and life threatening diseases. ... Genetic evidence has revolutionized scientific ...
(Date:3/22/2017)... 22, 2017 Good Start Genetics, a leading ... the 130 million covered lives mark through its most ... Texas . With newly signed contracts nationally ... enjoy strong payor acceptance based on the quality of ... genetic counseling, its industry-leading customer care and support and ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
Breaking Biology News(10 mins):